East Midlands Breathomics Pathology Node (EMBER)

我们的愿景是建立东米德兰兹呼吸组学病理节点(EMBER)作为一个卓越的中心，以确保开发新的呼气分析测试，以帮助了解疾病过程和临床决策。这将有助于开发新的方法来改进我们为正确的患者选择正确的治疗方法。在用于检测酒精水平的呼气测定仪的设置中，测量呼吸是我们都熟悉的，但可能不太为人所知的是，呼气中含有大量被称为挥发性有机化合物(VOC)的物质，这些物质来自肺部本身和更远的器官。最近的技术进步使这些VOCs的模式和数量能够在医院、医生诊所和可能在家里的患者中快速测量。这些物质的模式因疾病而异，可以区分同一疾病的不同类型。呼气测试有用的临床条件的范围非常大。EMBER最初将重点关注呼吸道感染、肺癌、慢性呼吸系统疾病(如哮喘和慢性阻塞性肺疾病)以及心血管疾病(如心力衰竭)。推动呼气分析作为常规测试的主要障碍是，它的发展需要汇集一支由呼吸分析专家组成的大型多学科科学家和临床医生团队，与NHS、行业和患者合作，将这些想法变为现实。东米德兰兹郡拥有一群独特而一致的临床和分析研究人员，他们来自莱斯特大学(UOL)、莱斯特大学NHS信托基金(UHL)和拉夫堡大学(LU)，他们在临床研究、分析化学、数据管理和复杂数据的数学分析方面具有优势。EMBER将集中这些综合优势，并协调与行业合作伙伴的现有合作，以创建一个具有临界质量的全国领先的呼吸分析中心，以建立世界级的临床新技术交付，并培训今天和未来的科学家和医疗保健专业人员。Ember将提供近距离患者和遥感技术来分析呼吸。我们将在不同的疾病和不同的医疗保健环境，如急症医院、二级和初级保健以及家庭中严格测试这些技术。我们将包括弱势患者群体，如患有复杂多种疾病的老年人和血液检测更具挑战性的儿童。EMBER将确保这些测试的有效性，从而通过帮助做出正确的决定来为患者选择正确的治疗，从而使它们的应用带来经济和健康好处。

Our vision is to establish the East Midlands Breathomics Pathology Node (EMBER) as a centre-of-excellence to ensure the development of novel breath analysis tests to help understand disease processes and clinical decision making. This will help develop new ways to improve the way we can chose the right treatment for the right patient. Measuring breath is familar to us all in the setting of the breathalyser to detect alcohol levels, but perhaps less well known is that exhaled breath contains lots of substances known as volatile organic compounds (VOCs) derived from the lung itself and from more distant organs. Recent advances in technology allow the pattern and quantity of these VOCs to be measured rapidly in patients in hospital, the doctors clinic and potentially at home. The patterns of these substances varies between diseases and can distinguish between different types of the same condition. The range of clinical conditions for which breath tests could be useful is very large. EMBER will intially focus upon respiratory infections, lung cancer, chronic respiratory disease such as asthma and chronic obstructive pulmonary disease, and cardiovascular disorders such as heart failure. The main barrier to advancing breath analysis as a routine test is that its development requires bringing together a large multi-disciplinary team of scientists and clinicans that are experts in breath analysis to work with the NHS, industry and patients to make these ideas a reality. The East Midlands has a unique and congruent group of clinical and analytical researchers drawn from the University of Leicester (UoL), the University Hospitals of Leicester NHS Trust (UHL) and Loughborough University (LU) with strengths in clinical research, analytical chemistry, data management and mathematical analysis of complex data. EMBER will focus these combined strengths, and co-ordinates existing collaborations with industry partners to create a nationally-leading centre in breath analysis with the critical mass to establish world-class delivery of new technology to the clinic, and training today's and the future scientists and health care professionals. EMBER will deliver near-patient and remote sensing technologies to analyse breath. We shall rigorously test these technologies in different diseases and in different health care settings such as acute hospitals, secondary and primary care and in the home. We shall include vulnerable patient groups such as the elderly with complicated multiple diseases and children in whom blood tests are more challenging. EMBER will ensure the usefulness of these tests so that their application brings economic and health benefits by helping to make the right decisions in choosing the right treatment for patients.